IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

doi:10.1016/j.jhep.2014.03.039

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

Journal of hepatology - 1 Aug 2014

Eslam Mohammed, Leung Reynold, Romero-Gomez Manuel, Mangia Alessandra, Irving William L, Sheridan David, Spengler Ulrich, Mollison Lindsay, Cheng Wendy, Bugianesi Elisabetta, McLeod Duncan, Zaitoun Abed M, Attino Vito, Goeltz Diane, Nattermann Jacob, Douglas Mark, Booth David R, George Jacob, Ahlenstiel Golo

Abstract excerpt

BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection. Whether IFNL3 SNPs influence treatment response in genotype 2 and 3 (HCV-2/3) infection remains controversial. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to IFNL3 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed

Identifiers

PMID: 24768758
DOI: 10.1016/j.jhep.2014.03.039

Genes

IFNL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.